Skip to content
Psychiatrist.com Logo
  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Advanced Search

Menu

  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Sign in Subscribe

Clinical Topics

View All
  • Addiction
  • ADHD
  • Alzheimer’s Disease
  • Anxiety
  • Bipolar Disorder
  • Depression
  • Movement Disorders
  • Neurology
  • OCD
  • Psychopharmacology
  • PTSD and Trauma
  • Schizophrenia/Schizoaffective Disorders
  • Sleep
  • Tardive Dyskinesia
  • View All

Collections

View All
  • Academic Highlights
  • Auvelity: Information from Industry
  • Banner Alzheimer’s Institute
  • Clinical & Practical Psychopharmacology
  • Early Career Psychiatrists
  • Focus on Childhood and Adolescent Mental Health
  • Focus on Geriatric Psychiatry
  • Focus on Psychotherapy
  • Focus on Suicide
  • Focus on Psychosis
  • Focus on Women’s Mental Health
  • Rounds in the General Hospital
  • UZEDY: Information from Industry
  • View All
Back to top Open menu arrow
Download PDF Reprints
No sections available

The Journal of
Clinical Psychiatry

Free access
Schizophrenia/Schizoaffective Disorders

Letter to the Editor September 1, 2003

Reply to Polypharmacy in Schizophrenia: A Fuzzy Concept

Stephen M. Stahl

J Clin Psychiatry 2003;64(9):1132-1132

Article Abstract

Letter to the Editor

Reply to Polypharmacy in Schizophrenia: A Fuzzy Concept

 

About the Authors

  • Stephen M. Stahl
    View full profile
Download Free PDF

This PDF is free for all visitors!

Related News Articles

New Clues Why Schizophrenia Patients Hear Voices How Social Thinking Shapes Recovery in Early Schizophrenia Weekly Mind Reader: Cognitive Impairments and Schizophrenia

Sponsored

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia
Explore two real-world schizophrenia cases with Roueen Rafeyan, MD and Melissa Vitale, PMHNP as they discuss challenges with medication adherence, transitioning to long-acting injectables (LAIs), and personalizing treatment strategies to improve patient outcomes.

Related JCP Articles

Evaluating the Transfer of Lurasidone Into Human Milk Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder The Superiority of Clozapine Over SGAs in Patients With Treatment-Resistant Schizophrenia

Related PCC Articles

Schizophrenia With Diphenhydramine Abuse NMS After Clozapine and ECT N-Acetylcysteine for Psychogenic Polydipsia
Cover of The Journal of Clinical Psychiatry, September 2025 issue, featuring article titles on postpartum distress, aripiprazole monohydrate injectables for schizophrenia and bipolar disorder, and other psychiatric topics.

Vol 86 • 2025 • Number 3

Read the Current Issue

Original Research

Postpartum Distress in Women With and Without ADHD

Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report

Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report

In Memoriam

In Memoriam: Terence A. Ketter, MD

Narrative Review

Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice

Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report

View current Issue

Related Articles

JCP
Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?
Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...
Xintong Mu, Hiroyoshi Takeuchi
JCP
Asenapine, Aggression, and Affinity
Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.
Rif S. El-Mallakh
JCP
A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole
Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.
Barbara Mintzes, Alain Braillon, Florian Naudet, et al

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Read the full report
Figure shows a syringe and vials with title on aripiprazole monohydrate LAI use in schizophrenia and a red READ NOW button.

Subscribe to read
more articles

Subscribe
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

ELSEWHERE:

  • ABOUT
  • ADVERTISERS
  • MEDIA RELATIONS
  • REPRINTS & PERMISSIONS
  • CONTACT US
  • CUSTOMER SUPPORT

FOLLOW US:

  • X
  • FACEBOOK
  • INSTAGRAM
  • LINKEDIN
  • THREADS
  • BLUESKY
  • SIGN IN

  • JOIN THE EMAIL LIST


SUBSCRIBE NOW
An image of the Psychiatrist.com logo mark
  • Privacy Policy
  • Terms of Use
  • Physicians Postgraduate Press, Inc.
  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • © Copyright 2025 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians
  • Sitemap